Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2OTHER_GOV 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 107Neoplasms 80Colorectal Neoplasms 54Uterine Cervical Neoplasms 29Stomach Neoplasms 29Lung Neoplasms 27Rectal Neoplasms 25Prostatic Neoplasms 25Colonic Neoplasms 24Polycystic Ovary Syndrome 22Pancreatic Neoplasms 22Head and Neck Neoplasms 17Endometrial Neoplasms 17Carcinoma, Non-Small-Cell Lung 16Carcinoma, Hepatocellular 16Pain 15Neoplasm Metastasis 15Motor Activity 15Esophageal Neoplasms 15Ovarian Neoplasms 13Urinary Bladder Neoplasms 11Lymphoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Pain, Postoperative 10Melanoma 10Thyroid Neoplasms 9Pilonidal Sinus 9Multiple Myeloma 9Gastrointestinal Neoplasms 9Sarcopenia 8

Interventions

pyrotinib 1Trastuzumab 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × OTHER_GOV × HER2 Positive Breast Cancer × Clear all
NCT03735966 2022-12-01

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.

Henan Cancer Hospital

Phase 2 Completed
75 enrolled
Breast

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡